Abstract
Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated activity in renal cell carcinoma and is now widely used in the palliative treatment of patients with metastatic renal cell carcinoma. It is generally well tolerated but has been associated with a low incidence of grade 3 and 4 toxicities including fatigue, diarrhea, anorexia, mucositis, skin toxicity, immune thrombocytopenic purpura, hypertension, hypothyroidism, cytopenias, and decreased cardiac ejection fraction. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Several medications have been implicated in causing TTP-HUS including clopidogrel, mitomycin C, cisplatin. In this report, we describe a case of atypical HUS-microangiopathic hemolytic anemia during treatment with sunitinib in a patient with metastatic renal cell carcinoma. To our knowledge, this is the fourth case of microangiopathic hemolytic anemia associated with sunitinib described in the literature and the first case with fatal outcome despite treatment with plasmapheresis, dialysis, and withdrawal of sunitinib.
| Original language | English |
|---|---|
| Journal | American Journal of Therapeutics |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2012 |
Fingerprint
Keywords
- microangiopathic hemolytic anemia
- renal failure
- sunitinib
- Sutent
- thrombocytopenia
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. / Talebi, Tony N.; Stefanovic, Alexandra; Merchan, Jaime R; Lian, Eric; Silva, Orlando.
In: American Journal of Therapeutics, Vol. 19, No. 4, 01.07.2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome
AU - Talebi, Tony N.
AU - Stefanovic, Alexandra
AU - Merchan, Jaime R
AU - Lian, Eric
AU - Silva, Orlando
PY - 2012/7/1
Y1 - 2012/7/1
N2 - Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated activity in renal cell carcinoma and is now widely used in the palliative treatment of patients with metastatic renal cell carcinoma. It is generally well tolerated but has been associated with a low incidence of grade 3 and 4 toxicities including fatigue, diarrhea, anorexia, mucositis, skin toxicity, immune thrombocytopenic purpura, hypertension, hypothyroidism, cytopenias, and decreased cardiac ejection fraction. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Several medications have been implicated in causing TTP-HUS including clopidogrel, mitomycin C, cisplatin. In this report, we describe a case of atypical HUS-microangiopathic hemolytic anemia during treatment with sunitinib in a patient with metastatic renal cell carcinoma. To our knowledge, this is the fourth case of microangiopathic hemolytic anemia associated with sunitinib described in the literature and the first case with fatal outcome despite treatment with plasmapheresis, dialysis, and withdrawal of sunitinib.
AB - Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated activity in renal cell carcinoma and is now widely used in the palliative treatment of patients with metastatic renal cell carcinoma. It is generally well tolerated but has been associated with a low incidence of grade 3 and 4 toxicities including fatigue, diarrhea, anorexia, mucositis, skin toxicity, immune thrombocytopenic purpura, hypertension, hypothyroidism, cytopenias, and decreased cardiac ejection fraction. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Several medications have been implicated in causing TTP-HUS including clopidogrel, mitomycin C, cisplatin. In this report, we describe a case of atypical HUS-microangiopathic hemolytic anemia during treatment with sunitinib in a patient with metastatic renal cell carcinoma. To our knowledge, this is the fourth case of microangiopathic hemolytic anemia associated with sunitinib described in the literature and the first case with fatal outcome despite treatment with plasmapheresis, dialysis, and withdrawal of sunitinib.
KW - microangiopathic hemolytic anemia
KW - renal failure
KW - sunitinib
KW - Sutent
KW - thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=84863701899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863701899&partnerID=8YFLogxK
U2 - 10.1097/MJT.0b013e3181eefe8b
DO - 10.1097/MJT.0b013e3181eefe8b
M3 - Article
C2 - 21403468
AN - SCOPUS:84863701899
VL - 19
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
SN - 1075-2765
IS - 4
ER -